Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BEAM

Beam Therapeutics Inc.

Healthcare | Biotechnology

No licensed closing price on file for BEAM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.67

Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:49 UTC.

What Beam Therapeutics Inc. does

Beam Therapeutics is a biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies individual DNA bases without creating double-stranded breaks in DNA. The company has assembled an integrated platform that combines gene editing technologies with delivery systems and internal manufacturing capabilities.

Summarized from Beam Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.67
Debt/equity0.09

Revenue, margins & earnings

FY2021: net loss $371M on revenue $52M$52MFY2021FY2022: net loss $289M on revenue $61M$61MFY2022FY2023: net loss $133M on revenue $378M$378MFY2023FY2024: net loss $377M on revenue $64M$64MFY2024FY2025: net loss $80M on revenue $140M$140MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16CEOOption exercise25,000$25.8K
  • 2026-10-16CEOStock Option (Right to Buy)Option exercise-25,000—
  • 2026-10-16CEOSale-25,000$599.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Beam Therapeutics Inc. do?

Beam Therapeutics is a biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies individual DNA bases without creating double-stranded breaks in DNA.

When did BEAM last file with the SEC?

Beam Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:49 UTC. This page is also available as JSON at /api/data?ticker=BEAM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BEAM and 5,000+ tickers.

Create a free account — keep BEAM
For your agent
GET /api/data?ticker=BEAM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt